XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | 0.69 | 0.42 | -39.13% | $171.2M | ❌ Miss | -16.85% | -28.01% | — |
| 2026-02-26 | Q4 2025 | 0.91 | 0.73 | -19.78% | $183.1M | ❌ Miss | -15.06% | -22.84% | -28.24% |
| 2025-11-06 |
| Q3 2025 |
| 0.79 |
| 0.93 |
| +17.72% |
| $191.8M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | 0.70 | 0.85 | +21.43% | $174.4M | ✅ Beat | +4.07% | +39.73% | +36.08% |
| 2025-02-27 | Q4 2024 | 0.94 | 0.92 | -2.13% | $186.5M | ❌ Miss | -9.72% | -10.07% | -7.94% |
| 2024-11-06 | Q3 2024 | 0.99 | 0.96 | -3.03% | $191.2M | ❌ Miss | -13.69% | -14.83% | -17.98% |
| 2024-08-07 | Q2 2024 | 0.77 | 0.94 | +22.08% | $182.4M | ✅ Beat | +13.29% | +9.13% | +16.69% |
| 2024-05-08 | Q1 2024 | 0.74 | 1.04 | +40.54% | $171.8M | ✅ Beat | +0.52% | +0.54% | -3.55% |
Showing last 8 quarters.